Clinical Observation of Neurokinin-1 Antagonist Preventing Multiple-day Chemotherapy-induced Nausea and Vomiting
-
摘要:目的
比较神经激肽-1受体抑制剂阿瑞匹坦三联方案与传统两联方案预防中高度催吐化疗方案分次给药所致恶心呕吐的疗效和安全性。
方法对102例化疗患者前瞻性对照研究的数据进行中期分析，其中49例患者接受5-羟色胺-3受体抑制剂联合和托烷司琼两联止吐方案，53例患者接受神经激肽-1受体抑制剂阿瑞匹坦联合5-羟色胺-3受体抑制剂和托烷司琼的三联止吐方案；采用Kaplan-Meier曲线比较两组第一次呕吐发生时间，FLIE量表评价恶心呕吐生活质量；评价阿瑞匹坦的相关不良反应。
结果（1）主要终点指标三联方案CR率优于两联方案（P < 0.05）。次要指标AP和DP的CR率比较，差异均有统计学意义（均P < 0.05）；（2）三联方案较两联方案的第一次呕吐发生时间晚（P < 0.05）；每例FLIE量表大于108分表示对生活质量无影响，两组差异有统计学意义（P < 0.05）。（3）阿瑞匹坦的相关不良反应主要为上腹胀痛或便秘。
结论三联止吐方案在中高度催吐性化疗方案分次用药所致恶心呕吐防治中疗效较好，安全可耐受。
Abstract:ObjectiveTo compare the effect and safety of 5-HT3 and tropisetron combined with neurokinin-1 antagonist aprepitant or not for the prevention of highly and moderately emetogenic multiple-day chemotherapy-induced nausea and vomiting (CINV).
MethodsThere were 53 patients received 5-HT3 and tropisetron combined with aprepitant (aprepitant group) and 49 patients received 5-HT3 and tropisetron (standard group). The primary end-points of the study were the CR in the overall phase (OP)(0-120h) between aprepitant group and standard group. The first time of vomiting between two groups was compared by Kaplan-Meier curves. The impact of CINV on the quality of life was assessed by the Functional Living Index-Emesis (FLIE). Aprepitant-related side-effect was also recorded.
Results(1) The primary end-points CR during overall phase were 83.0% vs. 53.1% between the aprepitant group and standard group (P < 0.05). The secondary end-points CR during acute phase and delay phase were 94.3% vs. 75.5%, 84.9% vs. 49.0% between two groups respectively (P < 0.05). (2) It was observed longer time to first emesis in the aprepitant group than standard group from Kaplan-Meier curves. The score≥108 which meant no effect on quality of life assessed by FLIE were 48.0% and 20.8% between two groups (P < 0.05). (3) The main aprepitant-related side-effects were upper abdominal pain and constipation.
ConclusionIt should been recommended that 5-HT3 and tropisetron combined neurokinin-1 antagonist aprepitant for the prevention of highly and moderately emetogenic multiple-day chemotherapy-induced nausea and vomiting have better effect and safety than only 5-HT3 and tropisetron.
-
Key words:
- Aprepitant /
- Chemotherapy /
- Vomiting /
- Multiple-day chemotherapy
-
-
[1] Hesketh PJ. Chemotherapy-induced nausea and vomiting[J]. N Engl J Med, 2008, 358(23): 2482-94. doi: 10.1056/NEJMra0706547
[2] Hickok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community[J]. Cancer, 2003, 97(11): 2880-6. doi: 10.1002/(ISSN)1097-0142
[3] Wiser W, Berger A. Practical management of chemotherapy-induced nausea and vomiting[J]. Oncology (Williston Park), 2005, 19(5): 637-45. https://www.researchgate.net/publication/7797763_Practical_management_of_chemotherapy-induced_nausea_and_vomiting
[4] Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group[J]. J Clin Oncol, 2003, 21(22): 4112-9. doi: 10.1200/JCO.2003.01.095
[5] Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America[J]. Cancer, 2003, 97(12): 3090-8. doi: 10.1002/(ISSN)1097-0142
[6] Hu Z, Cheng Y, Zhang H, et al. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase Ⅲ trial[J]. Support Care Cancer, 2014, 22(4): 979-87. doi: 10.1007/s00520-013-2043-9
[7] McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone[J]. Clin Pharmacol Ther, 2003, 74(1): 17-24. doi: 10.1016/S0009-9236(03)00066-3
[8] Martin AR, Pearson JD, Cai B, et al. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall[J]. Support Care Cancer, 2003, 11(8): 522-7. doi: 10.1007/s00520-003-0482-4
[9] Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy[J]. J Support Oncol, 2006, 4(1): 35-41, 52. https://www.researchgate.net/publication/7328689_Measuring_the_maintenance_of_daily_life_activities_using_the_functional_living_index-emesis_FLIE_in_patients_receiving_moderately_emetogenic_chemotherapy
[10] Martin AR, Carides AD, Pearson JD, et al. Functional relevance of antiemetic control:experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant[J]. Eur J Cancer, 2003, 39(10): 1395-401. doi: 10.1016/S0959-8049(03)00299-5
[11] Tang DH, Malone DC. A network meta-analysis on the efficacy of serotonin type 3 receptor antagonists used in adults during the first 24 hours for postoperative nausea and vomiting prophylaxis[J]. Clin Ther, 2012, 34(2): 282-94. doi: 10.1016/j.clinthera.2012.01.007
[12] Takahashi T, Hoshi E, Takagi M, et al. Multicenter, phase Ⅱ, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin[J]. Cancer Sci, 2010, 101(11): 2455-61. doi: 10.1111/j.1349-7006.2010.01689.x
[13] Wilder-Smith OH, Borgeat A, Chappuis P, et al. Urinary serotonin metabolite excretion during cisplatin chemotherapy[J]. Cancer, 1993, 72(7): 2239-41. doi: 10.1002/(ISSN)1097-0142
[14] Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists[J]. Eur J Cancer, 2003, 39(8): 1074-80. doi: 10.1016/S0959-8049(02)00674-3
[15] Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy[J]. J Clin Oncol, 2005, 23(12): 2822-30. doi: 10.1200/JCO.2005.09.050
[16] 董爽, 于世英.肿瘤化疗所致恶心呕吐现状调查[J].中国循证医学杂志, 2013, 13(6): 687-91. doi: 10.7507/1672-2531.20130122 Dong S, Yu SY. Status survey on chemotherapy-induced nausea and vomiting[J]. Zhongguo Xun Zheng Yi Xue Za Zhi, 2013, 13(6): 687-91. doi: 10.7507/1672-2531.20130122
下载:
计量
- 文章访问数: 1188
- HTML全文浏览量: 505
- PDF下载量: 316
